285 related articles for article (PubMed ID: 31839432)
1. Normal BMI predicts the survival benefits of inductive docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced oral squamous cell carcinoma.
Zhao TC; Liang SY; Ju WT; Liu Y; Tan YR; Zhu DW; Zhang CP; Zhang ZY; Zhong LP
Clin Nutr; 2020 Sep; 39(9):2751-2758. PubMed ID: 31839432
[TBL] [Abstract][Full Text] [Related]
2. GDF15 is a potential predictive biomarker for TPF induction chemotherapy and promotes tumorigenesis and progression in oral squamous cell carcinoma.
Yang CZ; Ma J; Zhu DW; Liu Y; Montgomery B; Wang LZ; Li J; Zhang ZY; Zhang CP; Zhong LP
Ann Oncol; 2014 Jun; 25(6):1215-22. PubMed ID: 24669014
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
Zhong LP; Zhang CP; Ren GX; Guo W; William WN; Sun J; Zhu HG; Tu WY; Li J; Cai YL; Wang LZ; Fan XD; Wang ZH; Hu YJ; Ji T; Yang WJ; Ye WM; Li J; He Y; Wang YA; Xu LQ; Wang BS; Kies MS; Lee JJ; Myers JN; Zhang ZY
J Clin Oncol; 2013 Feb; 31(6):744-51. PubMed ID: 23129742
[TBL] [Abstract][Full Text] [Related]
4. A prospective phase II randomized study of docetaxel combined with lobaplatin versus TPF regimen induction chemotherapy followed by concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma.
Zhang M; Chen Y; Wu W; Jin F; Li Y; Long J; Luo X; Gong X; Chen X; Liu L; Tang H; Wang Z
J Cancer Res Clin Oncol; 2023 Dec; 149(20):18081-18091. PubMed ID: 37985501
[TBL] [Abstract][Full Text] [Related]
5. Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma.
Zhong LP; Zhang CP; Ren GX; Guo W; William WN; Hong CS; Sun J; Zhu HG; Tu WY; Li J; Cai YL; Yin QM; Wang LZ; Wang ZH; Hu YJ; Ji T; Yang WJ; Ye WM; Li J; He Y; Wang YA; Xu LQ; Zhuang Z; Lee JJ; Myers JN; Zhang ZY
Oncotarget; 2015 Jul; 6(21):18707-14. PubMed ID: 26124084
[TBL] [Abstract][Full Text] [Related]
6. Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: a phase II study.
Hsieh CY; Lein MY; Yang SN; Wang YC; Lin YJ; Lin CY; Hua CH; Tsai MH; Lin CC
BMC Cancer; 2020 Sep; 20(1):832. PubMed ID: 32873270
[TBL] [Abstract][Full Text] [Related]
7. Elevated cyclin D1 expression is predictive for a benefit from TPF induction chemotherapy in oral squamous cell carcinoma patients with advanced nodal disease.
Zhong LP; Zhu DW; William WN; Liu Y; Ma J; Yang CZ; Yang X; Wang LZ; Li J; Myers JN; Lee JJ; Zhang CP; Zhang ZY
Mol Cancer Ther; 2013 Jun; 12(6):1112-21. PubMed ID: 23515614
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil combined with cisplatin concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: a matched pair analysis.
Teo M; Karakaya E; Young CA; Dyker KE; Coyle C; Sen M; Prestwich RJ
Clin Oncol (R Coll Radiol); 2013 Nov; 25(11):647-53. PubMed ID: 23948462
[TBL] [Abstract][Full Text] [Related]
9. A multicenter randomized phase II trial of hyperthermia combined with TPF induction chemotherapy compared with TPF induction chemotherapy in locally advanced resectable oral squamous cell carcinoma.
Ren G; Ju H; Wu Y; Song H; Ma X; Ge M; Qiu W; Chen Y; He Y; Zhuang Q; Meng J; Guo W
Int J Hyperthermia; 2021; 38(1):939-947. PubMed ID: 34134574
[TBL] [Abstract][Full Text] [Related]
10. Low Annexin A1 expression predicts benefit from induction chemotherapy in oral cancer patients with moderate or poor pathologic differentiation grade.
Zhu DW; Liu Y; Yang X; Yang CZ; Ma J; Yang X; Qiao JK; Wang LZ; Li J; Zhang CP; Zhang ZY; Zhong LP
BMC Cancer; 2013 Jun; 13():301. PubMed ID: 23786757
[TBL] [Abstract][Full Text] [Related]
11. Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation.
Janoray G; Pointreau Y; Garaud P; Chapet S; Alfonsi M; Sire C; Jadaud E; Calais G
J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26681800
[TBL] [Abstract][Full Text] [Related]
12. Comparison of carboplatin-paclitaxel to docetaxel-cisplatin-5-flurouracil induction chemotherapy followed by concurrent chemoradiation for locally advanced head and neck cancer.
Herman LC; Chen L; Garnett A; Feldman LE; Smith B; Weichselbaum RR; Spiotto MT
Oral Oncol; 2014 Jan; 50(1):52-8. PubMed ID: 24055193
[TBL] [Abstract][Full Text] [Related]
13. Cyclin D1 overexpression enhances chemosensitivity to TPF chemotherapeutic agents via the caspase-3 pathway in oral cancer.
Hu YJ; Sun WW; Zhao TC; Liu Y; Zhu DW; Wang LZ; Li J; Zhang CP; Zhang ZY; Zhong LP
Oncol Lett; 2020 Nov; 20(5):154. PubMed ID: 32934722
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and feasibility of docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy for locally advanced head and neck squamous cell carcinoma classified as clinical nodal stage N2c, N3, or N2b with supraclavicular lymph node metastases.
Izawa N; Onozawa Y; Hikosaka T; Hamauchi S; Tsushima T; Todaka A; Machida N; Haraguchi Y; Ogawa H; Nishimura T; Nakagawa M; Fuke T; Iida Y; Kamijo T; Onitsuka T; Boku N; Yasui H; Yokota T
Int J Clin Oncol; 2015 Jun; 20(3):455-62. PubMed ID: 25248339
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel and cisplatin induction chemotherapy with or without fluorouracil in locoregionally advanced nasopharyngeal carcinoma: A retrospective propensity score matching analysis.
Tao HY; Zhan ZJ; Qiu WZ; Liao K; Yuan YW; Zheng RH
Asia Pac J Clin Oncol; 2022 Apr; 18(2):e111-e118. PubMed ID: 33945215
[TBL] [Abstract][Full Text] [Related]
16. Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma.
Haddad RI; Massarelli E; Lee JJ; Lin HY; Hutcheson K; Lewis J; Garden AS; Blumenschein GR; William WN; Pharaon RR; Tishler RB; Glisson BS; Pickering C; Gold KA; Johnson FM; Rabinowits G; Ginsberg LE; Williams MD; Myers J; Kies MS; Papadimitrakopoulou V
Ann Oncol; 2019 Mar; 30(3):471-477. PubMed ID: 30596812
[TBL] [Abstract][Full Text] [Related]
17. Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis.
Liu GY; Lv X; Wu YS; Mao MJ; Ye YF; Yu YH; Liang H; Yang J; Ke LR; Qiu WZ; Huang XJ; Li WZ; Guo X; Xiang YQ; Xia WX
Cancer Commun (Lond); 2018 May; 38(1):21. PubMed ID: 29764487
[TBL] [Abstract][Full Text] [Related]
18. Decreased Annexin A1 expression enhances sensitivity to docetaxel, cisplatin and 5-fluorouracil combination induction chemotherapy in oral squamous cell carcinoma.
Sun W; Zhao T; Aladelusi TO; Ju W; Zhang Z; Zhong L; Zhu D
J Oral Pathol Med; 2021 Sep; 50(8):795-802. PubMed ID: 34157171
[TBL] [Abstract][Full Text] [Related]
19. Elevated growth differentiating factor 15 expression predicts long-term benefit of docetaxel, cisplatin and 5-fluorouracil induction chemotherapy in patients with oral cancer.
Tang X; Hu YJ; Ju WT; Fu Y; Sun WW; Liu Y; Tan YR; Wang LZ; Li J; Tu YY; Zhang CP; Zhang ZY; Zhong LP
Oncol Lett; 2018 May; 15(5):8118-8124. PubMed ID: 29731919
[TBL] [Abstract][Full Text] [Related]
20. Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials.
Kong L; Zhang Y; Hu C; Guo Y; Lu JJ
Cancer; 2017 Jun; 123(12):2258-2267. PubMed ID: 28192641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
